$CVRX
CVRx, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007786 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $11.81M $10.77M $7.979M
YoY Change 24.28% 34.98% 95.76%
Cost Of Revenue $1.900M $1.615M $1.328M
YoY Change 25.25% 21.61% 39.94%
Gross Profit $9.907M $9.155M $6.651M
YoY Change 24.1% 37.65% 112.7%
Gross Profit Margin 83.91% 85.0% 83.36%
Selling, General & Admin $21.12M $28.33M $15.40M
YoY Change 28.32% 84.0% 42.87%
% of Gross Profit 213.13% 309.45% 231.5%
Research & Development $2.765M $3.057M $3.416M
YoY Change -15.7% -10.51% 51.28%
% of Gross Profit 27.91% 33.39% 51.36%
Depreciation & Amortization $141.0K $131.0K $129.0K
YoY Change 11.02% 1.55% 108.06%
% of Gross Profit 1.42% 1.43% 1.94%
Operating Expenses $23.88M $31.39M $18.81M
YoY Change 21.0% 66.84% 44.33%
Operating Profit -$13.97M -$22.23M -$12.16M
YoY Change 18.9% 82.8% 22.75%
Interest Expense -$959.0K -$960.0K $240.0K
YoY Change 99.38% -500.0%
% of Operating Profit
Other Income/Expense, Net $944.0K $1.044M $1.062M
YoY Change 53.25% -1.69% -1963.16%
Pretax Income -$13.99M -$22.15M -$11.34M
YoY Change 20.41% 95.31% 13.8%
Income Tax $41.00K $38.00K $34.00K
% Of Pretax Income
Net Earnings -$14.03M -$22.19M -$11.37M
YoY Change 20.41% 95.06% 13.84%
Net Earnings / Revenue -118.82% -206.0% -142.55%
Basic Earnings Per Share -$0.65 -$1.04 -$0.55
Diluted Earnings Per Share -$0.65 -$1.05 -$0.55
COMMON SHARES
Basic Shares Outstanding 21.60M 20.93M 20.69M
Diluted Shares Outstanding 21.63M 21.23M 20.69M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.40M $80.12M $103.3M
YoY Change -22.48% -22.43% -21.27%
Cash & Equivalents $70.40M $80.12M $103.3M
Short-Term Investments
Other Short-Term Assets $1.762M $2.656M $2.631M
YoY Change -50.27% 0.95% 25.89%
Inventory $11.22M $11.06M $8.241M
Prepaid Expenses
Receivables $8.606M $8.495M $6.434M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $91.99M $102.3M $120.6M
YoY Change -17.87% -15.14% -15.2%
LONG-TERM ASSETS
Property, Plant & Equipment $2.763M $3.823M $1.805M
YoY Change -5.83% 111.8% 9.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.00K $26.00K $27.00K
YoY Change -3.7% -3.7% 3.85%
Total Long-Term Assets $3.989M $3.849M $2.109M
YoY Change 34.72% 82.5% -4.31%
TOTAL ASSETS
Total Short-Term Assets $91.99M $102.3M $120.6M
Total Long-Term Assets $3.989M $3.849M $2.109M
Total Assets $95.98M $106.2M $122.7M
YoY Change -16.52% -13.46% -15.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.516M $2.608M $1.996M
YoY Change 19.88% 30.66% 24.21%
Accrued Expenses $5.610M $5.790M $5.961M
YoY Change -6.38% -2.87% 19.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.126M $8.398M $7.957M
YoY Change 2.25% 5.54% 20.71%
LONG-TERM LIABILITIES
Long-Term Debt $29.32M $29.27M $14.22M
YoY Change 105.7% 105.87%
Other Long-Term Liabilities $1.265M $2.242M $815.0K
YoY Change -30.91% 175.09% 15.44%
Total Long-Term Liabilities $30.58M $31.51M $15.03M
YoY Change 90.15% 109.62% 2029.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.126M $8.398M $7.957M
Total Long-Term Liabilities $30.58M $31.51M $15.03M
Total Liabilities $40.73M $39.91M $23.05M
YoY Change 62.87% 73.15% 203.2%
SHAREHOLDERS EQUITY
Retained Earnings -$513.6M -$499.6M -$447.6M
YoY Change 11.84% 11.62% 10.58%
Common Stock $569.1M $566.0M $547.4M
YoY Change 3.59% 3.4% 1.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $55.25M $66.26M $99.64M
YoY Change
Total Liabilities & Shareholders Equity $95.98M $106.2M $122.7M
YoY Change -16.52% -13.46% -15.04%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$14.03M -$22.19M -$11.37M
YoY Change 20.41% 95.06% 13.84%
Depreciation, Depletion And Amortization $141.0K $131.0K $129.0K
YoY Change 11.02% 1.55% 108.06%
Cash From Operating Activities -$9.830M -$10.90M -$10.25M
YoY Change -23.25% 6.31% -3.71%
INVESTING ACTIVITIES
Capital Expenditures $355.0K $917.0K $240.0K
YoY Change 148.25% 282.08% -18.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$355.0K -$917.0K -$240.0K
YoY Change 148.25% 282.08% -18.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 472.0K 1.362M 7.568M
YoY Change -0.21% -82.0% 15666.67%
NET CHANGE
Cash From Operating Activities -9.830M -10.90M -10.25M
Cash From Investing Activities -355.0K -917.0K -240.0K
Cash From Financing Activities 472.0K 1.362M 7.568M
Net Change In Cash -9.713M -10.45M -2.918M
YoY Change -22.16% 258.26% -73.22%
FREE CASH FLOW
Cash From Operating Activities -$9.830M -$10.90M -$10.25M
Capital Expenditures $355.0K $917.0K $240.0K
Free Cash Flow -$10.18M -$11.81M -$10.49M
YoY Change -21.36% 12.62% -4.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21232009
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20693224
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21232009
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20693224
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001235912
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21593173
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20879199
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40545
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CVRx, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1983744
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9201 West Broadway Avenue
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 650
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55445
CY2024Q1 dei City Area Code
CityAreaCode
763
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
416-2840
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock,
CY2024Q1 dei Trading Symbol
TradingSymbol
CVRX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21595576
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80115000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90569000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
647000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
508000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8495000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7551000
CY2024Q1 us-gaap Inventory Net
InventoryNet
11056000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2656000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2987000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
102322000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
112090000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2549000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1274000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2024Q1 us-gaap Assets
Assets
106171000
CY2023Q4 us-gaap Assets
Assets
115229000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2608000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1884000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5790000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8398000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7864000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29270000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29222000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1092000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1150000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1036000
CY2024Q1 us-gaap Liabilities
Liabilities
39910000
CY2023Q4 us-gaap Liabilities
Liabilities
39282000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21593173
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20879199
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
216000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
565822000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
553326000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-499567000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-477381000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-210000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-207000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
66261000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106171000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115229000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10770000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7979000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
1615000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1328000
CY2024Q1 us-gaap Gross Profit
GrossProfit
9155000
CY2023Q1 us-gaap Gross Profit
GrossProfit
6651000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3057000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3416000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28330000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15397000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
31387000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
18813000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22232000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12162000
CY2024Q1 us-gaap Interest Expense
InterestExpense
960000
CY2023Q1 us-gaap Interest Expense
InterestExpense
240000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1044000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1062000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22148000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11340000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11374000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22189000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11371000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21232009
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21232009
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20693224
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20693224
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
815000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11141000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
547000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22186000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
66261000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109180000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1705000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11374000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
99642000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-22186000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11374000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11141000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1705000
CY2024Q1 us-gaap Depreciation
Depreciation
131000
CY2023Q1 us-gaap Depreciation
Depreciation
129000
CY2024Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
48000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
31000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
944000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
930000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
73000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1284000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-345000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1591000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
724000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
277000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-82000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-398000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10896000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10249000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
917000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
240000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-917000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-240000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
815000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
547000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2024Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0
CY2023Q1 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
7500000
CY2024Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
60000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1362000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7568000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10454000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2918000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90569000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106194000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80115000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103276000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
770000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
188000
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
4544000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4714000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
750000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
654000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5762000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5615000
CY2024Q1 us-gaap Inventory Net
InventoryNet
11056000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5468000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4551000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2919000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2788000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2549000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q1 us-gaap Depreciation
Depreciation
131000
CY2023Q1 us-gaap Depreciation
Depreciation
129000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2106000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3335000
CY2024Q1 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
898000
CY2023Q4 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
770000
CY2024Q1 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
591000
CY2023Q4 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
411000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
284000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
220000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
270000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27000
CY2024Q1 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
242000
CY2023Q4 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
277000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
218000
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
145000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
125000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
797000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
584000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5790000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10000000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
730000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29270000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1274000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1092000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1331000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1391000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
233000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
350000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
362000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
374000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
223000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1542000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
211000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1331000
CY2024Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y4M24D
CY2024Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.067
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108406
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
14.92
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4488845
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.77
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
97266000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2014489
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.94
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1180316
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.20
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
86610
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.41
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5236408
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.12
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37108000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2711871
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.96
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
27885000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11141000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1705000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11141000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1705000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
27900000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
8400000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11374000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21232009
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20693224
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5344814
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5142736
CY2024Q1 us-gaap Contractual Obligation
ContractualObligation
0
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2024Q1 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
200000
CY2023Q1 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
0
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10770000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7979000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-007786-index-headers.html Edgar Link pending
0001558370-24-007786-index.html Edgar Link pending
0001558370-24-007786.txt Edgar Link pending
0001558370-24-007786-xbrl.zip Edgar Link pending
cvrx-20240331.xsd Edgar Link pending
cvrx-20240331x10q.htm Edgar Link pending
cvrx-20240331xex31d1.htm Edgar Link pending
cvrx-20240331xex31d2.htm Edgar Link pending
cvrx-20240331xex32d1.htm Edgar Link pending
cvrx-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
cvrx-20240331_def.xml Edgar Link unprocessable
cvrx-20240331_lab.xml Edgar Link unprocessable
cvrx-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cvrx-20240331x10q_htm.xml Edgar Link completed
cvrx-20240331_cal.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending